

Operational Summary

for the First Half of the Fiscal Year Ending March 31, 2017

November 8, 2016

Mitsubishi Chemical Holdings Corporation

Table of Contents

Consolidated Financial Statements for FY2016 1H	Page No.	Consolidated Financial Statements Forecasts for FY2016	Page No.
Statement of Operations	... 4	Statement of Operations	... 12
Sales Revenue and Core Operating Income by Business Segment	... 5	Sales Revenue and Core Operating Income by Business Segment	... 13
Analysis of Core Operating Income	... 7	Cash Dividends	... 15
Special Items	... 8	References	
Statement of Cash Flows	... 9	Capital Expenditure, Depreciation & Amortization, R&D Expenses, and Number of Employees by Business Segment	... 17
Statement of Financial Positions	... 10	[FY2015 Quarterly Data (IFRS)] Statement of Operations	... 18
		[FY2015 Quarterly Data (IFRS)] Sales Revenue and Core Operating Income by Business Segment	... 19

Mitsubishi Chemical Holdings Corporation has adopted IFRS starting with FY2016 1Q.
The numerical values in FY2015 based on J-GAAP have been translated to the values based on IFRS.

List of Abbreviations

FY2016:	April 1, 2016 - March 31, 2017
	1st Quarter ("1Q") of FY2016: April 1, 2016 - June 30, 2016
	2nd Quarter ("2Q") of FY2016: July 1, 2016 - September 30, 2016
	1st Half ("1H") of FY2016: April 1, 2016 - September 30, 2016
	2nd Half ("2H") of FY2016: October 1, 2016 - March 31, 2017
FY2015:	April 1, 2015 - March 31, 2016
	1st Half ("1H") of FY2015: April 1, 2015 - September 30, 2015
MCHC:	Mitsubishi Chemical Holdings Corporation
MCC:	Mitsubishi Chemical Corporation
MTPC:	Mitsubishi Tanabe Pharma Corporation
MPI:	Mitsubishi Plastics, Inc.
MRC:	Mitsubishi Rayon Co., Ltd.
LSII:	Life Science Institute, Inc.
TNSC:	Taiyo Nippon Sanso Corporation

(Note)

Divisional numbers into following "business sub-segments" under the business segments of Designed Materials, Health Care, Chemicals, or Polymers are approximation for reference purpose only;

Functional Products	Petrochemicals
Performance	Carbon
Chemicals	
Pharmaceuticals	Industrial Gases
Diagnostics, Clinical Testing and API	Polyolefins and Advanced Polymers
	MMA Monomers and Polymers

Consolidated Statements of Operations

		107.9	102.9	105.4	121.7	(16.3)		
Exchange Rate (¥/\$)								
Naphtha Price (¥/kl)		31,600	31,300	31,500	48,000	(16,500)		
(Billions of Yen)								
		1Q	2Q	FY2016 1H	FY2015 1H	Change	%	
Continuing Operations * 2	Sales Revenue	794.6	791.7	1,586.3	1,777.9	(191.6)	-11%	
	Core Operating Income *1	70.6	65.7	136.3	153.6	(17.3)	-11%	
	Special Items	(5.6)	(10.6)	(16.2)	(0.2)	(16.0)		
	Operating Income	65.0	55.1	120.1	153.4	(33.3)	-22%	
	Financial Income/Expenses (Dividend included above)	(5.0)	(3.5)	(8.5)	(5.8)	(2.7)		
	(Foreign Exchange Gain/Loss included above)	[2.5]	[0.2]	[2.7]	[3.5]	[(0.8)]		
		[(3.9)]	[(0.7)]	[(4.6)]	[(1.5)]	[(3.1)]		
	Earnings Before Taxes	60.0	51.6	111.6	147.6	(36.0)		
	Income Taxes	(19.9)	*3 17.5	(2.4)	(45.1)	42.7		
	Net Income from Continuing Operations	40.1	69.1	109.2	102.5	6.7		
	Net Income from Discontinued Operations	1.1	(1.2)	(0.1)	(5.8)	5.7		
Net Income	41.2	67.9	109.1	96.7	12.4			
Net Income Attributable to Owners of the Parent	26.1	53.1	79.2	67.8	11.4	17%		
Net Income Attributable to Non-Controlling Interests	15.1	14.8	29.9	28.9	1.0			
		4.0	3.4	7.4	8.0	(0.6)		

*1 Equity income included.

*2 Discontinued operations are not included.

Sales revenue and core operating income of discontinued operations are as follows:

(Billions of Yen)		
	FY2016 1H	FY2015 1H
Sales Revenue	54.7	67.6
Core Operating Income	1.4	(3.9)

*3 Deferred tax assets relating to the terephtharic acid business transfer are recognized.

Consolidated Net Sales and Core Operating Income by Business Segment

(Billions of Yen)

		1Q	2Q	FY2016 1H	FY2015 1H	Change
Total Consolidated	Sales Revenue	794.6	791.7	1,586.3	1,777.9	(191.6)
	Core Operating Income	70.6	65.7	136.3	153.6	(17.3)
Electronics Applications	Sales Revenue	26.0	26.0	52.0	58.4	(6.4)
	Core Operating Income	(0.3)	(0.3)	(0.6)	0.6	(1.2) (a)
Functional Products	Sales Revenue	135.2	136.7	271.9	288.1	(16.2)
	Core Operating Income	11.5	12.0	23.5	21.0	2.5 (b)
Performance Chemicals	Sales Revenue	62.1	59.9	122.0	120.4	1.6
	Core Operating Income	9.0	7.7	16.7	15.6	1.1 (c)
Designed Materials	Sales Revenue	197.3	196.6	393.9	408.5	(14.6)
	Core Operating Income	20.5	19.7	40.2	36.6	3.6
Pharmaceuticals	Sales Revenue	105.5	98.6	204.1	202.0	2.1
	Core Operating Income	29.0	19.0	48.0	49.7	(1.7) (d)
Diagnostics, Clinical Testing and API	Sales Revenue	29.4	29.9	59.3	60.2	(0.9)
	Core Operating Income	0.1	0.9	1.0	2.3	(1.3) (e)
Healthcare	Sales Revenue	134.9	128.5	263.4	262.2	1.2
	Core Operating Income	29.1	19.9	49.0	52.0	(3.0)

*All figures are approximation for reference purpose only.

Major reasons for the change:

- (a) Profit decreased due to the impact of the yen's appreciation and other factors, despite the effect of rationalizations.
- (b) Profit increased due to stronger sales of films for displays including *CLEARFIT* and a drop in raw material prices of films for food packing materials and other products, despite the impact of the yen's appreciation and lower sales of fibers and textiles.
- (c) Profit increased due to a drop in raw material prices and higher sales of lithium-ion battery materials, despite the impact of the yen's appreciation.
- (d) Profit decreased due mainly to the negative impact of the NHI drug price revisions, despite increased sales of priority products and vaccine business and higher royalty revenues from out-licensing drugs
- (e) Profit decreased due to lower sales of capsules and pharmaceutical equipment for capsules and tablets.

Consolidated Net Sales and Core Operating Income by Business Segment (Continued)

					(Billions of Yen)	
		1Q	2Q	FY2016 1H	FY2015 1H	Change
Petrochemicals *1	Sales Revenue	53.1	52.0	105.1	170.8	(65.7)
	Core Operating Income	(2.2)	(5.2)	(7.4)	10.2	(17.6) (a)
Carbon	Sales Revenue	39.7	42.6	82.3	95.3	(13.0)
	Core Operating Income	(0.1)	0.7	0.6	4.1	(3.5) (b)
Industrial Gases	Sales Revenue	131.7	133.8	265.5	280.7	(15.2)
	Core Operating Income	11.5	12.9	24.4	21.0	3.4 (c)
Chemicals	Sales Revenue	224.5	228.4	452.9	546.8	(93.9)
	Core Operating Income	9.2	8.4	17.6	35.3	(17.7)
Polyolefins and Advanced Polymers	Sales Revenue	101.1	99.6	200.7	235.2	(34.5)
	Core Operating Income	6.0	8.2	14.2	16.2	(2.0) (d)
MMA Monomers and Polymers	Sales Revenue	68.9	67.2	136.1	166.8	(30.7)
	Core Operating Income	7.4	9.3	16.7	13.8	2.9 (e)
Polymers	Sales Revenue	170.0	166.8	336.8	402.0	(65.2)
	Core Operating Income	13.4	17.5	30.9	30.0	0.9
Others	Sales Revenue	41.9	45.4	87.3	100.0	(12.7)
	Core Operating Income	0.8	2.4	3.2	3.0	0.2
Corporate	Sales Revenue	-	-	-	-	-
	Core Operating Income	(2.1)	(1.9)	(4.0)	(3.9)	(0.1)

*All figures are approximation for reference purpose only.

*1 Discontinued operations are not included.

Major reasons for the change:

- (a) Profit decreased due mainly to worsening petrochemical market conditions compared to the strong market conditions in FY2015 1Q, and a larger than anticipated scale of scheduled maintenance and repairs.
- (b) Profit for coke decreased due mainly to reduced margins in export.
- (c) Profit increased due to lower costs accompanying a drop in raw material and fuel costs and the impact of newly consolidated subsidiary for Australian business.
- (d) Profit decreased due to a larger than anticipated scale of scheduled maintenance and repairs, despite recovery of the buy-sell spreads in polyolefin business.
- (e) Profit increased due mainly to firm sales of MMA in Europe and North America.

	(Billions of Yen)				
Inventory valuation gain/loss	1Q	2Q	FY2016 1H	FY2015 1H	Change
Chemicals (Petrochemicals) *1	0.1	(0.6)	(0.5)	(0.8)	0.3
Chemicals (Carbon)	(0.3)	(0.4)	(0.7)	(0.6)	(0.1)
Polymers	(2.7)	(1.4)	(4.1)	(5.1)	1.0
Total	(2.9)	(2.4)	(5.3)	(6.5)	1.2

Analysis of Core Operating Income

(Billions of Yen)

	FY2016 1H	FY2015 1H	Change				
				Price	Volume	Fixed Cost	Others *1
Total Consolidated	136.3	153.6	(17.3)	(23.5)	(2.0)	11.9	(3.7)
Electronics Applications	(0.6)	0.6	(1.2)	(2.9)	0.5	1.9	(0.7)
Designed Materials	40.2	36.6	3.6	(3.2)	5.8	2.1	(1.1)
Healthcare	49.0	52.0	(3.0)	(7.2)	3.2	3.9	(2.9)
Chemicals *2	17.6	35.3	(17.7)	(11.5)	(9.3)	1.8	1.3
Polymers	30.9	30.0	0.9	1.3	(2.5)	2.1	0.0
Others	3.2	3.0	0.2	0.0	0.3	0.1	(0.2)
Corporate	(4.0)	(3.9)	(0.1)	0.0	0.0	0.0	(0.1)

*1 Including the impact of inventory valuation gain/loss and differences in equity income, etc.

*2 Discontinued operations are not included.

Consolidated Special Items

	(Billions of Yen)				
	1Q	2Q	FY2016 1H	FY2015 1H	Change
Total Special Items	(5.6)	(10.6)	(16.2)	(0.2)	(16.0)
Impairment loss	(0.9)	(7.0)	(7.9)	(2.6)	(5.3)
Losses during the break period of operation due to earthquake disaster	(1.9)	(0.4)	*1 (2.3)	-	(2.3)
Special retirement expenses	(1.4)	(0.6)	(2.0)	(0.0)	(2.0)
Prior service cost	(0.8)	-	(0.8)	-	(0.8)
Gain on sale of property, plant and equipment	0.6	-	0.6	1.0	(0.4)
Gain on step acquisitions	-	-	-	1.9	(1.9)
Loss on sale of intercompany securities	-	-	-	(1.4)	1.4
Others	(1.2)	(2.6)	*1 (3.8)	0.9	(4.7)

*1 Including the impact of Kumamoto earthquake-related losses (4.0 billion yen)

*2 Discontinued operations are not included.

[Special Items by Business Segment]

Electronics Applications	(0.6)	(0.2)	(0.8)	(2.0)	1.2
Designed Materials	(2.9)	(4.9)	*1 (7.8)	1.4	(9.2)
Healthcare	0.1	(1.0)	(0.9)	(0.4)	(0.5)
Chemicals *2	(0.3)	(3.3)	(3.6)	0.4	(4.0)
Polymers	(1.9)	(0.0)	(1.9)	0.0	(1.9)
Others	-	(0.0)	(0.0)	-	(0.0)
Corporate	(0.0)	(1.2)	(1.2)	0.4	(1.6)

Consolidated Cash Flows

	Based on statements of cash flows		Adjusted cash flows*		<reference> Target for FY2016 Forecast (announced on May 13)
	FY2016 1H	FY2015 1H	FY2016 1H	FY2015 1H	
Net cash provided by operating activities	195.6	67.8	195.6	172.6	340.0
Income before income taxes	111.7	142.1	111.7	142.1	198.0
Depreciation and amortization	84.4	90.6	84.4	90.6	180.0
Change in operating receivables/payables	31.6	(58.8)	31.6	23.2	28.0
Change in Inventories	12.3	(10.9)	12.3	(10.9)	
Others	(44.4)	(95.2)	(44.4)	(72.4)	(66.0)
Net cash used in investment activities	(124.3)	(1.6)	(174.3)	(91.7)	(240.0)
Capital expenditure	(96.0)	(93.8)	(96.0)	(93.8)	(244.0)
Sale of assets	8.0	18.1	8.0	18.1	4.0
Investment and loans receivable, etc.	(36.3)	74.1	(86.3)	(16.0)	
Free cash flow	71.3	66.2	21.3	80.9	100.0
Net cash used in financing activities	(23.9)	7.4			
Interest bearing debts	45.3	31.0			
Additional acquisition of consolidated subsidiaries' stocks	(39.8)	(0.7)			
Dividends, etc.	(29.4)	(22.9)			
Increase (Decrease) in cash and cash equivalents	47.4	73.6			
Effect of exchange rate changes and change in scope of consolidation	*1 (32.9)	(1.0)			
Cash and cash equivalents at the beginning of the period	267.1	252.7			
Cash and cash equivalents at the end of the period	281.6	325.3			

*1 Including transfer to assets classified as held for sale (10.5 billion yen).

*"Adjusted cash flows" is calculated by excluding the following items respectively for convenience.

(2Q of FY 2016)

a) Excluding cash flows from investment of surplus funds.

(2Q of FY 2015)

a) Excluding cash flows from investment of surplus funds.

b) Excluding the influence by first-time adoption of IFRS regarding securitization.

Amounts of the influence	(Billions of Yen)
Increase of account receivables	(82.0)
Others	(22.8)
CF for operating activities	(104.8)
CF for financing activities	104.8
Change in cash and cash equivalents	-

Consolidated Statement of Financial Positions

	Sep. 30, 2016	Mar. 31, 2016	Change		Sep. 30, 2016	Mar. 31, 2016	Change
Cash and cash equivalents	281.6	267.1	14.5	Interest-bearing debts	1,563.2	1,579.6	(16.4)
Trade receivables	715.9	769.1	(53.2)	Trade payables	380.5	394.1	(13.6)
Inventories	504.4	549.5	(45.1)	Other liabilities	632.3	653.9	(21.6)
Other current assets	259.3	271.0	(11.7)	Total liabilities	2,576.0	2,627.6	(51.6)
Total current assets	1,761.2	1,856.7	(95.5)	Shareholders' equity	1,031.2	962.2	69.0
Tangible and Intangible fixed assets	1,577.3	1,599.0	(21.7)	Other components of equity	(38.7)	10.0	(48.7)
Goodwill	293.5	267.9	25.6	Total equity attributable to owners of the parent	992.5	972.2	20.3
Investment and other non-current assets	515.7	500.2	15.5	Non-controlling interests	579.2	624.0	(44.8)
Total non-current assets	2,386.5	2,367.1	19.4	Total equity	1,571.7	1,596.2	(24.5)
Total assets	4,147.7	4,223.8	(76.1)	Total liabilities and equity	4,147.7	4,223.8	(76.1)
				Net interest-bearing debts (*1)	1,153.7	1,134.4	19.3
				Net D/E ratio	1.16	1.17	(0.01)
				Ratio of equity attributable to owners of the parent to total assets	23.9%	23.0%	0.9%

(Billions of Yen)

*1. Net interest-bearing debts
 = interest bearing debts (1,563.2 billion yen)
 - {cash and cash equivalents (281.6 billion yen) + investments of surplus funds (127.9 billion yen)}

Consolidated Financial Results Forecasts for FY2016

The forecasts for FY2016 full-year consolidated financial results were announced on October 28.

Consolidated Statements of Operations

Exchange Rate (¥/\$)	105.4	100.0	102.7	110.0	(7.3)	120.2
Naphtha Price (¥/kl)	31,500	32,000	31,800	37,000	(5,200)	42,800

		(Billions of Yen)				<reference>		
	Continuing Operations	FY2016 1H (Actual)	FY2016 2H (Forecast)	FY2016 Forecast	FY2016 Forecast (Announced on May 13)	Change	% to 1H Forecast	FY2015 (Actual)
		Sales Revenue	1,586.3	1,693.7	3,280.0	3,460.0	(180.0)	(5.2%)
Core Operating Income	136.3	122.7	259.0	234.5	24.5	10.4%	300.4	
Special Items	(16.2)	(13.8)	(30.0)	(24.0)	(6.0)		(31.7)	
Operating Income	120.1	108.9	229.0	210.5	18.5	8.8%	268.7	
Financial Income/Expenses	(8.5)	(6.5)	(15.0)	(11.5)	(3.5)		(15.9)	
Earnings Before Taxes	111.6	102.4	214.0	199.0	15.0	7.5%	252.8	
Income Taxes	(2.4)	(33.6)	(36.0)	(66.5)	30.5		(74.1)	
Net Income from Continuing Operations	109.2	68.8	178.0	132.5	45.5		178.7	
Net Income from Discontinued Operations*	(0.1)	1.1	1.0	(1.0)	2.0		(73.8)	
Net Income	109.1	69.9	179.0	131.5	47.5	36.1%	104.9	
Net Income Attributable to Owners of the Parent	79.2	45.8	125.0	80.0	45.0	56.3%	51.4	
Net Income Attributable to Non-Controlling Interests	29.9	24.1	54.0	51.5	2.5		53.5	

*1 Figures relating to the terephthalic acid business in India and China are recognized as "net income from discontinued operations."

Consolidated Revenue and Core Operating Income by Business Segment

					(Billions of Yen)	<reference>	
		FY2016 1H (Actual)	FY2016 2H (Forecast)	FY2016 Forecast	FY2016 Forecast (Announced on May 13)	Change	FY2015 (Actual)
Total Consolidated *1	Sales Revenue	1,586.3	1,693.7	3,280.0	3,460.0	(180.0)	3,543.4
	Core Operating Income	136.3	122.7	259.0	234.5	24.5	300.4
Electronics Applications	Sales Revenue	52.0	48.0	100.0	105.0	(5.0)	115.7
	Core Operating Income	(0.6)	(1.4)	(2.0)	(2.0)	0.0	(1.0)
Functional Products	Sales Revenue	271.9	283.1	555.0	580.0	(25.0)	580.8
	Core Operating Income	23.5	19.5	43.0	40.0	3.0	43.3
Performance Chemicals	Sales Revenue	122.0	133.0	255.0	255.0	0.0	244.8
	Core Operating Income	16.7	13.3	30.0	27.0	3.0	31.7
Designed Materials	Sales Revenue	393.9	416.1	810.0	835.0	(25.0)	825.6
	Core Operating Income	40.2	32.8	73.0	67.0	6.0	75.0
Pharmaceuticals	Sales Revenue	204.1	209.9	414.0	406.5	7.5	425.7
	Core Operating Income	48.0	37.0	85.0	77.0	8.0	107.0
Diagnostics, Clinical Testing and API	Sales Revenue	59.3	61.7	121.0	128.5	(7.5)	122.7
	Core Operating Income	1.0	2.0	3.0	5.0	(2.0)	5.2
Healthcare	Sales Revenue	263.4	271.6	535.0	535.0	0.0	548.4
	Core Operating Income	49.0	39.0	88.0	82.0	6.0	112.2

*All figures are approximation for reference purpose only.

*1 Discontinued operations are not included.

Consolidated Revenue and Core Operating Income by Business Segment (Continued)

		(Billions of Yen)					<reference>
		FY2016 1H (Actual)	FY2016 2H (Forecast)	FY2016 Forecast	FY2016 Forecast (Announced on May 13)	Change	FY2015 (Actual)
Petrochemicals *1	Sales Revenue	105.1	124.9	230.0	280.0	(50.0)	311.3
	Core Operating Income	(7.4)	(0.6)	(8.0)	0.5	(8.5)	8.0
Carbon	Sales Revenue	82.3	89.7	172.0	162.0	10.0	183.2
	Core Operating Income	0.6	2.4	3.0	3.0	0.0	4.9
Industrial Gases	Sales Revenue	265.5	297.5	563.0	603.0	(40.0)	587.1
	Core Operating Income	24.4	25.1	49.5	49.5	0.0	44.8
Chemicals *1	Sales Revenue	452.9	512.1	965.0	1,045.0	(80.0)	1,081.6
	Core Operating Income	17.6	26.9	44.5	53.0	(8.5)	57.7
Polyolefins and Advanced Polymers	Sales Revenue	200.7	209.3	410.0	430.0	(20.0)	460.5
	Core Operating Income	14.2	15.8	30.0	27.0	3.0	36.4
MMA Monomers and Polymers	Sales Revenue	136.1	133.9	270.0	300.0	(30.0)	305.8
	Core Operating Income	16.7	10.3	27.0	11.0	16.0	20.0
Polymers	Sales Revenue	336.8	343.2	680.0	730.0	(50.0)	766.3
	Core Operating Income	30.9	26.1	57.0	38.0	19.0	56.4
Others	Sales Revenue	87.3	102.7	190.0	210.0	(20.0)	205.8
	Core Operating Income	3.2	3.3	6.5	4.5	2.0	7.1
Corporate	Sales Revenue	-	-	-	-	-	-
	Core Operating Income	(4.0)	(4.0)	(8.0)	(8.0)	0.0	(7.0)

*All figures are approximation for reference purpose only.

*1 Discontinued operations are not included.

Cash Dividends

		FY2016	FY2015	FY2014	FY2013	FY2012
Cash dividends per share (Yen)	Interim	8	7	6	6	6
	Year-end	*1 8	8	7	6	6
	Total (Annual)	*1 16	15	13	12	12

*1 Forecast

References

Consolidated Capital Expenditure, Depreciation & Amortization, R&D Expenses, and Number of Employees by Business Segment

(Billions of Yen, until otherwise noted)

	Capital Expenditure		Depreciation & Amortization (excluding goodwill)		R&D Expenses		Number of Employees FY2016 1H (End of the period)
	FY2016 1H	FY2015 1H	FY2016 1H	FY2015 1H	FY2016 1H	FY2015 1H	
Electronics Applications	2.7	2.0	2.6	3.0	3.2	3.7	2,512
Designed Materials	22.9	21.2	20.7	20.2	10.8	10.5	18,479
Health Care	11.5	9.1	8.8	8.7	36.0	37.6	12,256
Chemicals	35.6	35.0	31.0	34.7	2.0	2.0	19,106
Polymers	25.5	16.4	19.1	21.7	5.9	7.4	8,361
Others	1.7	1.5	1.4	1.5	0.1	0.1	8,093
Corporate	0.1	0.8	0.8	0.8	2.1	2.3	685
Total	100.0	86.0	84.4	90.6	60.1	63.6	69,492

[FY2015 Quarterly Data (IFRS)]

Consolidated Statements of Operations

After excluding discontinued operations

Continuing Operations *2	Sales Revenue
	Core Operating Income *1
	Special Items
	Operating Income
	Financial Income/Expenses (Dividend included above) (Foreign Exchange Gain/Loss included above)
	Earnings Before Taxes
	Income Taxes
	Net Income from Continuing Operations
	Net Income from Discontinued Operations
	Net Income
Net Income Attributable to Owners of the Parent	
Net Income Attributable to Non-Controlling Interests	

(Billions of Yen)

1Q	2Q	FY2015 1H	3Q	4Q	FY2015 2H	FY2015
890.8	887.1	1,777.9	903.6	861.9	1,765.5	3,543.4
78.0	75.6	153.6	95.2	51.6	146.8	300.4
0.5	(0.7)	(0.2)	(19.4)	(12.1)	(31.5)	(31.7)
78.5	74.9	153.4	75.8	39.5	115.3	268.7
0.1	(5.9)	(5.8)	(2.6)	(7.5)	(10.1)	(15.9)
[3.3]	[0.2]	[3.5]	[1.9]	[0.1]	[2.0]	[5.5]
[0.8]	[(2.3)]	[(1.5)]	[(0.3)]	[(3.7)]	[(4.0)]	[(5.5)]
78.6	69.0	147.6	73.2	32.0	105.2	252.8
(27.5)	(17.6)	(45.1)	(23.2)	(5.8)	(29.0)	(74.1)
51.1	51.4	102.5	50.0	26.2	76.2	178.7
(0.1)	(5.7)	(5.8)	(65.8)	(2.2)	(68.0)	(73.8)
51.0	45.7	96.7	(15.8)	24.0	8.2	104.9
35.8	32.0	67.8	(33.9)	17.5	(16.4)	51.4
15.2	13.7	28.9	18.1	6.5	24.6	53.5
4.3	3.7	8.0	2.8	3.2	6.0	14.0

*1 Equity income included.

*2 Discontinued operations are not included.

[FY2015 Quarterly Data (IFRS)]

Consolidated Sales Revenue and Core Operating Income by Business Segment

(Billions of Yen)

After excluding discontinued operations		1Q	2Q	1H	3Q	4Q	2H	FY2015
Total Consolidated *1	Sales Revenue	890.8	887.1	1,777.9	903.6	861.9	1,765.5	3,543.4
	Core Operating Income	78.0	75.6	153.6	95.2	51.6	146.8	300.4
Electronics Applications	Sales Revenue	29.4	29.0	58.4	28.9	28.4	57.3	115.7
	Core Operating Income	(0.3)	0.9	0.6	(0.2)	(1.4)	(1.6)	(1.0)
Functional Products	Sales Revenue	142.0	146.1	288.1	149.2	143.5	292.7	580.8
	Core Operating Income	9.0	12.0	21.0	13.1	9.2	22.3	43.3
Performance Chemicals	Sales Revenue	59.8	60.6	120.4	61.7	62.7	124.4	244.8
	Core Operating Income	7.5	8.1	15.6	8.7	7.4	16.1	31.7
Designed Materials	Sales Revenue	201.8	206.7	408.5	210.9	206.2	417.1	825.6
	Core Operating Income	16.5	20.1	36.6	21.8	16.6	38.4	75.0
Pharmaceuticals	Sales Revenue	98.7	103.3	202.0	132.5	91.2	223.7	425.7
	Core Operating Income	25.2	24.5	49.7	45.6	11.7	57.3	107.0
Diagnostics, Clinical Testing and API	Sales Revenue	30.4	29.8	60.2	30.8	31.7	62.5	122.7
	Core Operating Income	1.9	0.4	2.3	2.0	0.9	2.9	5.2
Healthcare	Sales Revenue	129.1	133.1	262.2	163.3	122.9	286.2	548.4
	Core Operating Income	27.1	24.9	52.0	47.6	12.6	60.2	112.2

*All figures are approximation for reference purpose only.

*1 Discontinued operations are not included.

[FY2015 Quarterly Data (IFRS)]

Consolidated Sales Revenue and Core Operating Income by Business Segment (Continued)

After excluding discontinued operations		(Billions of Yen)						
		1Q	2Q	1H	3Q	4Q	2H	FY2015
Petrochemicals *1	Sales Revenue	88.0	82.8	170.8	75.4	65.1	140.5	311.3
	Core Operating Income	8.6	1.6	10.2	0.4	(2.6)	(2.2)	8.0
Carbon	Sales Revenue	49.6	45.7	95.3	45.2	42.7	87.9	183.2
	Core Operating Income	2.7	1.4	4.1	1.7	(0.9)	0.8	4.9
Industrial Gases	Sales Revenue	138.9	141.8	280.7	146.0	160.4	306.4	587.1
	Core Operating Income	10.4	10.6	21.0	13.6	10.2	23.8	44.8
Chemicals *1	Sales Revenue	276.5	270.3	546.8	266.6	268.2	534.8	1,081.6
	Core Operating Income	21.7	13.6	35.3	15.7	6.7	22.4	57.7
Polyolefins and Advanced Polymers	Sales Revenue	121.4	113.8	235.2	112.5	112.8	225.3	460.5
	Core Operating Income	7.4	8.8	16.2	9.0	11.2	20.2	36.4
MMA Monomers and Polymers	Sales Revenue	85.3	81.5	166.8	70.6	68.4	139.0	305.8
	Core Operating Income	6.7	7.1	13.8	1.0	5.2	6.2	20.0
Polymers	Sales Revenue	206.7	195.3	402.0	183.1	181.2	364.3	766.3
	Core Operating Income	14.1	15.9	30.0	10.0	16.4	26.4	56.4
Others	Sales Revenue	47.3	52.7	100.0	50.8	55.0	105.8	205.8
	Core Operating Income	0.6	2.4	3.0	1.5	2.6	4.1	7.1
Corporate	Sales Revenue	-	-	-	-	-	-	-
	Core Operating Income	(1.7)	(2.2)	(3.9)	(1.2)	(1.9)	(3.1)	(7.0)

*All figures are approximation for reference purpose only.

*1 Discontinued operations are not included.

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control.

Actual results could differ materially due to numerous factors, including without limitation, marketing conditions and the effects of industry competition.